Success Metrics

Clinical Success Rate

81.8%

Based on 9 completed trials

Completion Rate

82%(9/11)

Active Trials

1(5%)

Results Posted

100%(9 trials)

Terminated

2(11%)

Phase Distribution

Ph phase_2

21%

Ph phase_3

26%

Ph not_applicable

21%

Ph phase_4

16%

Ph early_phase_1

Ph phase_1

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution19 total trials

Early Phase 1First-in-human

1(5.3%)

Phase 1Safety & dosage

2(10.5%)

Phase 2Efficacy & side effects

4(21.1%)

Phase 3Large-scale testing

5(26.3%)

Phase 4Post-market surveillance

3(15.8%)

N/ANon-phased studies

4(21.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(9)

Terminated(3)

Other(4)

Detailed Status

Completed9

unknown4

Terminated2

Recruiting1

Enrolling by invitation1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

81.8%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (5.3%)

Phase 12 (10.5%)

Phase 24 (21.1%)

Phase 35 (26.3%)

Phase 43 (15.8%)

N/A4 (21.1%)

Trials by Status

recruiting15%

enrolling_by_invitation15%

terminated211%

unknown421%

completed947%

withdrawn15%

not_yet_recruiting15%

Recent Activity

1 active trials

Showing 5 of 19

completedphase_3

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

NCT02106494

recruitingphase_3

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

NCT07413809

enrolling_by_invitationnot_applicable

Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention

NCT05773950

completedphase_3

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

NCT05564286

not_yet_recruitingphase_4

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

NCT05841849

View all 19 trials

Clinical Trials (19)

Showing 19 of 19 trials

NCT02106494Phase 3

A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC

Completed

NCT07413809Phase 3

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

Recruiting

NCT05773950Not Applicable

Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention

Enrolling By Invitation

NCT05564286Phase 3

Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer

Completed

NCT05841849Phase 4

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Not Yet Recruiting

NCT04636632Phase 1

Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma

Completed

NCT02780609Phase 1

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Completed

NCT03035838Early Phase 1

Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury

Withdrawn

NCT05230654Not Applicable

Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs

Unknown

NCT04912271Phase 3

Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

Unknown

NCT04873284Not Applicable

Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients

Unknown

NCT01857232Phase 2

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

Completed

NCT01697579Phase 2

Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

Completed

NCT02519842Phase 3

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Terminated

NCT03586817Phase 4

PALONOSETRON X FOSAPREPITANT IN PONV

Unknown

NCT01874119Phase 2

Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma

Terminated

NCT01432015Phase 4

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Completed

NCT01736917Phase 2

Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors